These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

714 related items for PubMed ID: 16785064

  • 1. Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide.
    Hallemeier CL, Girgis MD, Blum WG, Brown RA, Khoury HJ, Devine SM, Vij R, Lin HS, DiPersio JF, Adkins DR.
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):749-57. PubMed ID: 16785064
    [Abstract] [Full Text] [Related]

  • 2. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N, Bornhäuser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG, Wandt H, Schäfer-Eckardt K, Beyer J, Kiehl M, Zander AR, German Cooperative Transplant Study Group.
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [Abstract] [Full Text] [Related]

  • 3. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED, Cioc A, Defor T, Dolan M, Weisdorf D.
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [Abstract] [Full Text] [Related]

  • 4. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB, Sampol A, Bernal MT, Piñana JL, Vazquez L, Ribera JM, Besalduch J, Moraleda JM, Carrera D, Brunet MS, Perez-Simón JA, Sierra J.
    J Clin Oncol; 2008 Feb 01; 26(4):577-84. PubMed ID: 18086801
    [Abstract] [Full Text] [Related]

  • 5. Outcomes of adults with acute myelogenous leukemia in remission given 550 cGy of single-exposure total body irradiation, cyclophosphamide, and unrelated donor bone marrow transplants.
    Hallemeier C, Girgis M, Blum W, Brown R, Khoury H, Goodnough LT, Vij R, Devine S, Wehde M, Postma S, Lin HS, Dipersio J, Adkins D.
    Biol Blood Marrow Transplant; 2004 May 01; 10(5):310-9. PubMed ID: 15111930
    [Abstract] [Full Text] [Related]

  • 6. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
    Kröger N, Schetelig J, Zabelina T, Krüger W, Renges H, Stute N, Schrum J, Kabisch H, Siegert W, Zander AR.
    Bone Marrow Transplant; 2001 Oct 01; 28(7):643-7. PubMed ID: 11704786
    [Abstract] [Full Text] [Related]

  • 7. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, Micozzi A, Fenu S, Laurenti L, Donato V, De Felice L, Arcese W.
    Haematologica; 2002 Jan 01; 87(1):52-8. PubMed ID: 11801465
    [Abstract] [Full Text] [Related]

  • 8. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.
    Alyea EP, Kim HT, Ho V, Cutler C, DeAngelo DJ, Stone R, Ritz J, Antin JH, Soiffer RJ.
    Biol Blood Marrow Transplant; 2006 Oct 01; 12(10):1047-55. PubMed ID: 17067911
    [Abstract] [Full Text] [Related]

  • 9. Long-term outcome after bone marrow transplantation for aplastic anemia using cyclophosphamide and total lymphoid irradiation as conditioning regimen.
    Inamoto Y, Suzuki R, Kuwatsuka Y, Yasuda T, Takahashi T, Tsujimura A, Sugimoto K, Oba T, Terakura S, Atsuta Y, Murata M, Ito M, Kodera Y, Miyamura K.
    Biol Blood Marrow Transplant; 2008 Jan 01; 14(1):43-9. PubMed ID: 18158960
    [Abstract] [Full Text] [Related]

  • 10. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
    Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ.
    J Clin Oncol; 2005 Aug 20; 23(24):5675-87. PubMed ID: 16110027
    [Abstract] [Full Text] [Related]

  • 11. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F, Copelan E, Crilley P, Bolwell B, Avalos B, Klein J, Territo M, Gajewski J.
    Bone Marrow Transplant; 1996 May 20; 17(5):685-9. PubMed ID: 8733682
    [Abstract] [Full Text] [Related]

  • 12. Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease.
    Chan GW, Foss FM, Klein AK, Sprague K, Miller KB.
    Biol Blood Marrow Transplant; 2003 Dec 20; 9(12):753-9. PubMed ID: 14677114
    [Abstract] [Full Text] [Related]

  • 13. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
    Chen YB, Coughlin E, Kennedy KF, Alyea EP, Armand P, Attar EC, Ballen KK, Cutler C, Dey BR, Koreth J, McAfee SL, Spitzer TR, Antin JH, Soiffer RJ, Ho VT.
    Biol Blood Marrow Transplant; 2013 Jun 20; 19(6):981-7. PubMed ID: 23562738
    [Abstract] [Full Text] [Related]

  • 14. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
    Huisman C, Meijer E, Petersen EJ, Lokhorst HM, Verdonck LF.
    Biol Blood Marrow Transplant; 2008 Feb 20; 14(2):181-6. PubMed ID: 18215778
    [Abstract] [Full Text] [Related]

  • 15. Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
    Saure C, Schroeder T, Zohren F, Groten A, Bruns I, Czibere A, Galonska L, Kondakci M, Weigelt C, Fenk R, Germing U, Haas R, Kobbe G.
    Biol Blood Marrow Transplant; 2012 Mar 20; 18(3):466-72. PubMed ID: 21963618
    [Abstract] [Full Text] [Related]

  • 16. Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up.
    Oyekunle AA, Kröger N, Zabelina T, Ayuk F, Schieder H, Renges H, Fehse N, Waschke O, Fehse B, Kabisch H, Zander AR.
    Bone Marrow Transplant; 2006 Jan 20; 37(1):45-50. PubMed ID: 16258531
    [Abstract] [Full Text] [Related]

  • 17. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.
    Bibawi S, Abi-Said D, Fayad L, Anderlini P, Ueno NT, Mehra R, Khouri I, Giralt S, Gajewski J, Donato M, Claxton D, Braunschweig I, van Besien K, Andreeff M, Andersson BS, Estey EH, Champlin R, Przepiorka D.
    Am J Hematol; 2001 Aug 20; 67(4):227-33. PubMed ID: 11443634
    [Abstract] [Full Text] [Related]

  • 18. Improved outcome for peripheral blood stem cell transplantation for advanced primary myelodysplastic syndrome.
    Solomon SR, Savani BN, Childs R, Montero A, Boss C, Read EJ, Leitman SF, Barrett AJ.
    Biol Blood Marrow Transplant; 2005 Aug 20; 11(8):619-26. PubMed ID: 16041312
    [Abstract] [Full Text] [Related]

  • 19. Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors.
    Demuynck H, Verhoef GE, Zachee P, Emonds MP, van der Schueren E, van den Berghe H, Vandenberghe P, Casteels-Van Daele M, Boogaerts MA.
    Bone Marrow Transplant; 1996 May 20; 17(5):745-51. PubMed ID: 8733692
    [Abstract] [Full Text] [Related]

  • 20. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
    Mori T, Aisa Y, Watanabe R, Yamazaki R, Kato J, Shimizu T, Shigematsu N, Kubo A, Yajima T, Hibi T, Ikeda Y, Okamoto S.
    Biol Blood Marrow Transplant; 2008 Jun 20; 14(6):651-7. PubMed ID: 18489990
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.